Chester County News and Community Website
WILMINGTON, DE — The Chemours Company (NYSE: CC) reported stronger second-quarter sales and adjusted earnings but swung to a net loss after booking charges tied to a $250 million settlement with …
Chemours Posts Higher Sales, Swings to Loss on $250M NJ PFAS Settlement Read More
CONSHOHOCKEN, PA — Hamilton Lane Incorporated (Nasdaq: HLNE) posted lower year-over-year earnings for its first fiscal quarter ended June 30, 2025, as weaker incentive fees weighed on revenue, though assets …
Hamilton Lane Reports Q1 Earnings Decline, Increases Dividend Read More
CONSHOHOCKEN, PA— AdaptHealth Corp. (NASDAQ: AHCO) reported a slight revenue decline in its second quarter results but remains confident in its long-term strategy, highlighting operational improvements, enhanced patient services, and …
AdaptHealth Reports Q2 Earnings Dip, Reaffirms Growth Strategy and Adjusts Full-Year Outlook Read More
PHILADELPHIA, PA — Aramark (NYSE: ARMK) delivered record third-quarter revenue and profitability, driven by strong base business performance, new client wins, and rising retention rates. The global food and facilities services …
Aramark Posts Record Revenue and Profitability in Q3, Eyes Strong Finish to Fiscal Year Read More
AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) reported a strong second quarter with revenue and profit growth fueled by solid performance in its U.S. Spine business and momentum across its …
Globus Medical Delivers Strong Q2 Results, Reaffirms 2025 Outlook Read More
WILMINGTON, DE — Acorn Energy, Inc. (Nasdaq: ACFN) reported robust second-quarter results, driven by continued execution of a major monitoring contract and growth in its recurring revenue model. The company also …
Acorn Energy Posts 55% Revenue Surge on Strength of Cell Tower Contract, Nasdaq Uplisting Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License Application (BLA) submission for its lead …
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported a second-quarter net loss of $15.4 million and a year-to-date loss of $30.5 million, as the company continues to invest in advancing …
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline Read More
WILMINGTON, DE — Enovis Corporation (NYSE: ENOV) reported solid second-quarter results, posting 7% year-over-year sales growth and raising its full-year financial guidance amid continued momentum in its orthopedic business segments.
Enovis Delivers 7% Sales Growth in Q2, Raises Full-Year Outlook Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biotechnology company advancing T cell-engaging bispecific antibodies for solid tumors, reported a second-quarter net loss of $8.8 million as it continues …
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 Read More